home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

2006 4th Annual Congress of International Drug Discovery Science and Technology (IDDST)

  January 18, 2006  

World High Technology Society, Dalian World Expo Center, Dalian and Xi'an, China
May 25-Jun. 2, 2006



Workshop I: Introduction to Drug Administration

Dr. Guozhong Rui, Director, Chinese Research and Commercialization Center for Medicinal Technology

Dr. Andrew Chang, Associate Director for Policy and Regulation, Division of Hematology , OBRR, CBER, FDA, USA

Dr. Emily Shacter, Chief, Laboratory of Biochemistry, Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, USA


Workshop II: International Venture Capital Training

Part I: How Multi-national Companies Protect and Leverage Intellectual Property Rights

Mr. Kening Li,Crowell & Moring, LLP, USA

Part II: How Universities/non-profit Research Organizations and Small Start-up Companies Protect and Leverage Intellectual Property Rights

The Speakers are Under Organizing!

Part III Introduction to U.S. Food and Drug Law and Regulations

The Speakers are Under Organizing!

Part IV Introduction to Practices in Front of the U.S. International Trade Commission (ITC) and Investigations

The Speakers are Under Organizing!


Keynote speech

Title: RNase P and the Inhibition of Gene Expression in Human Cells
Dr. Sidney Altman
, Nobel Prize laureates in Chemistry 1989

Title: Defining Innovation in 21st Century Medicine
Dr. Lee Babiss
, Vice President, Preclinical Research and Development. Hoffmann-La, Roche, Inc. USA


Session 1: Anti-Cardiovascular Diseases Drug Discovery & Development

Title: Nitric Oxide Donors Protect Myocardium Against Infarction

Dr. Guang-Wu Wang, Assistant Research Cardiologist, UCLA School of Medicine 

Title: (TBD)

Dr. Emery H.  Bresnick, Professor of Pharmacology, University of Wisconsin-Madison, USA 

Title: Pharmacogenomic and Pharmacoproteomic for Cardiovascular Drugs

Dr. Gvard Siest, Professor, Centre du Muicament, France


Session 2: Latest Advances in New Drug Discovery of Liver Diseases

Title: New Developments in Hepatitis C treatment

Dr. Bhupinder S. Anand, Professor, Baylor College of Medicine & Michael E. DeBakey VA Medical Center, Houston, Texas, USA

Title: Pharmacogenetics of Drug Metabolism Enzymes in Relation to Drug Toxicity and Disease Susceptibility Factors.

Dr. Glyn Steventon, Professor, King's College London, UK

Title: New Drug Discovery in Viral Models Herpes Simplex Viruses

Dr. Luis M Schang, Department of Biochemistry and Department of Molecular Microbiology and Immunology, Signal Transduction Research Group, University of Alberta, Canada

Title: Current Status of Antivirals for HBV and Novel Approaches Based on HBV-Host Interactions

Dr. William Chen Wei Ning, Associate Professor, Division of Chemical and Biomolecular Engineering, School of Chemical and Biomedical Engineering, College of Engineering, Nanyang Technological University, Singapore


Session 3: New Drug Discovery & Development in HIV & Serious Epidemic Infectious Diseases

Title: (TBD)

Dr. Genfa Zhou, President, Fusogen Pharmaceuticals, Inc., Tianjin, China

Title: (TBD)

Dr. Ian Woolley, Professor, Department of Infectious Disease and Clinical Epidemiology, Monash Medicine Centre, USA

Title: Blocking Viral Entry: A Complementary Strategy for HIV Therapy

Dr. Shibo Jiang, Head of Viral Immunology Laboratory, New York Blood Center, USA

Title: (TBD)

Dr. Stuart Le Grice, Chief, Resistance Mechanisms Laboratory and Chief, RT Biochemistry Section, HIV Drug Resistance Program, National Cancer Institute, USA

Title: Novel patented HIV protease inhibitors which act as inhibitors of Pglycoprotein

Dr. Andreas Hilgeroth, PD, Co-Editor von Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, Germany

Title: Anti-HIV drug and their prodrugs

Dr. Marina Kukhanova, Engelhardt Institute of Molecular Biology, Russia


Session 4: New Drug Development of Cancer /Tumors and Leukaemia

Title: (TBD)

Dr. Bin Liu, Assistant Professor, Department of Anesthesia, UCSF Comprehensive Cancer Center, USA

Title: (TBD)

Dr. Bozena Kaminska, Department of Cell Biology, Laboratory of Transcription Regulation, Nencki Institute of Experimental Biology, Poland

Title: Cyclooxygenase-1 and Bicistronic Cyclooxygenase-1/Prostacyclin Synthase Gene Transfer Protect Against Ischemic Cerebral Infarction

Dr. Kenneth K. Wu, Associate Director, Center for Vascular Biology, The Brown Foundation Institute of Molecular Medicine, USA

Title: (TBD)

Dr. Yong Jia, Department of Molecular Pharmacology, Abbott Bioresearch Center, Worcester, USA

Title: Screening and Preclinical Study of Anticancer Drugs

Dr. Weimin Fan, Professor of Pathology and Medicine, Member, Hollings Cancer Center, Medical University of South Carolina, USA

Title: Molecular Pncology and Targeted Cancer Therapy

Dr. Weikang Tao, Department of Cancer Research, Merck Research Laboratories, USA


Session 5: Anti-Diabetes and Anti-Metabolic Disorder Drug Discovery & Development

Session Chair: Dr. William Cho, Scientific Officer, Queen Elizabeth Hospital, Hong Kong, China

Title: Practice in Family Medicine and Diabetes Epidemiology and Biological Markers in Diabetes and Its Complications.

Dr. Deyi Zheng, Palmetto Health Richland Hospital/USC SOM

Title: Modulation of Mitochondrial Structure and Function and Mitochondrial Stress Signaling in Diabetes

Dr. Narayan G. Avadhani, Professor, University of Pennsylvania, USA

Title: (TBD)

Dr. Chun-Cheng Lin, Associate Research Fellow, Institute of Chemistry, Academia Sinica, Taiwan, China

Title: Proteomic and Medicinal Approaches to Diabetes and Its Complications
Dr. William Cho,
Scientific Officer, Queen Elizabeth Hospital, Hong Kong, China

Title: (TBD)

Dr. James R. Gavin, Professor, Clinical Professor of Medicine Emory University of Medicine, Executive Vice President for Clinical Affairs, Healing Our Village, Inc., USA


Session 6: Drug Discovery of Alzheimer's Disease (AD), Parkinson's Disease (PD)and Related Aging Disorders

Title: Novel Multifunctional Neuroprotective-Neurorescue Anti-Alzheimer, Anti-Parkinson Drugs with Various Cns Targets 

Dr. Moussa . B. H. Youdim, National Parkinson Foundation (US) Centers of Excellence for Neurodegenerative Diseases Technion-Faculty of Medicine Haifa, Israel

Title: New potential treatments (eg. Anti-oxidants and omega 3 polyunsaturated fatty acids) against Alzheimer’s disease and other aging related didorders, from an epidemiological point of view.

Dr. Pascale Barberger – Gateau, Epidemiology, Public Health and Development, French

Title: The Investigation of Potential Biomarkers for the Diagnosis of Alzheimer's Disease in Human Cerebrospinal Fluid.

Dr. Alex E. Roher, Director, Sun Health Research Institute, USA

Title: Synthesis and Development of Potent and Selective mGluR2/3 Agonists

Dr. Lushi Tan, Merck & Co., Inc., USA

Title: Developing Neuropsychiatric Research and Services in China

Dr. Roger Bullock, Kingshill Research Centre, Victoria Hospital, Swindon UK

Title: Drug Treatment in Alzheimer's Disease

Dr. Esther Ebeneezer, University Hospital Kuala Lumpu


Session 7: Master Medicinal Chemistry to Develop More Potent, Safe and New Anti-Major Disease Medicines

Title: Glucokinase Activators

Dr. Ramakanth Sarabu, Hoffmann-La Roche, USA

Title: Involved in the Identification of the Dasatinib (BMS-354825) as a Dual Src/Abl Kinase Inhibitor

Dr. Ping Chen, Bristol-Myers Squibb, USA

Title: (TBD)

Dr. K V Sashidhara, Scientist, Central Drug Research Institute Medicinal, India

Title: Structure-Activity Relationship of β-MSH Derived Melanocortin-4 Receptor Agonists and Its Potential Use as an Anti-obesity Agent

Dr. Liang Z. Yan, Lilly Research Laboratories, A Division of Eli Lilly & Co., Lilly Corporate Center, USA

Title: Studies on Nitric Oxide-donating Drugs

Dr. Yihua Zhang, Drug Discovery Center, China Pharmaceutical University


Session 8: Globalization, Standardization and Modernization of TCM

Title: Innovation Drug R&D Based on the Traditional Chinese Herbs

Dr. Ke Liu, CEO, Research Institute of Luye Pharmaceutical (RILP), China

Title: (TBD)

Dr. Weishuo Fang, Associate Dean, Chinese Academy of Medical Science & Peking Union Medical College

Title: (TBD)

Dr. Shide Luo, Institute of Kunming Botany, Chinese Academy of Science, China


Biopharmaceutical Company Venture Capital Forum

Title: Venture Capital Investors' Perspective on Biotechnology.

Mr. Kening Li,Crowell & Moring, LLP, USA

Title: (TBD)

Mr. David Zhang, Executive Vice President, THE WI HARPOR Group, USA

Title: (TBD)

Mr. M C Tang, Chairman, MBA, Chairman, World Tech Ventures and TAGC Bio-Ventures, USA

Title: (TBD)

Mr. Tianping Wu, President, HK Wonderful Investment Group, ShangHai branch, China

Organized by: BIT
Invited Speakers: Dr. Sidney Altman, Nobel Prize laureates in Chemistry 1989, USA

Dr. Lee Babiss, Vice President, Preclinical Research and Development. Hoffmann-La, Roche, Inc., USA

Dr.Steven Dentali, VP, Scientific and Technical Affairs, American Herbal Products Association, USA

Dr.Emily Shacter, Chief, Laboratory of Biochemistry, Division of Therapeutic Proteins, USA

Dr.Iwao Ojima, Distinguished Professor and Director, Institute of Chemical Biology & Drug Discovery (ICB&DD), USA
Deadline for Abstracts: April 25, 2006
Registration: May 25, 2006
E-mail: emily@iddst.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.